Fly News Breaks for November 19, 2019
RHHBY, NVO, DRNA
Nov 19, 2019 | 08:18 EDT
SVB Leerink analyst Mani Foroohar raised his price target for Dicerna (DRNA) to $30 from $26 and maintained an Outperform rating after the company announced a collaboration with Novo Nordisk (NVO) to develop candidates for liver-related cardiometabolic diseases. In a research note to investors, Foroohar says that while Dicerna's stock has traded up about 30% since the announcement of a partnership with Roche (RHHBY), it remains undervalued.
News For DRNA;NVO;RHHBY From the Last 2 Days
Oct 27, 2020 | 07:41 EDT
Oncolytics Biotech (ONCY) announced a new multi-indication gastrointestinal, or GI, cancer study to be managed by AIO, a leading academic cooperative medical oncology group based in Germany. The phase 1/2 trial, known as GOBLET, will investigate the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, in patients with metastatic pancreatic, metastatic colorectal and advanced anal cancers. The GOBLET study will make use of a new master clinical supply agreement between Oncolytics and Roche (RHHBY). Per the agreement, Roche will supply atezolizumab for use in Oncolytics' clinical development plan.